We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Autoimmunity Markers Prevalence Assessed in Immune Thrombocytopenia

By LabMedica International staff writers
Posted on 17 Dec 2019
Print article
Image: The cobas c 502 is a medium throughput clinical chemistry module that performs photometric assay tests for a wide range of analytes (Photo courtesy of Roche).
Image: The cobas c 502 is a medium throughput clinical chemistry module that performs photometric assay tests for a wide range of analytes (Photo courtesy of Roche).
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder resulting from decreased platelet production and increased platelet destruction. Platelet autoantibodies in ITP lead to both acceleration of platelet destruction in the spleen and inhibition of platelet production by bone marrow megakaryocytes.

Although current guidelines recommend against routine testing of patients with ITP for autoimmune markers in the absence of disease-specific symptoms, there is general recognition that they frequently have autoantibodies associated with other autoimmune disorders in the absence of any clinical evidence of these disorders.

A number of studies have suggested that patients with ITP have a higher prevalence than the general population of positive autoimmune markers, including (ANA), rheumatoid factor (RF), anticardiolipin antibodies (ACL) immunoglobulin G (IgG) and immunoglobulin G (IgM), red blood cell direct antiglobulin test (DAT), antithyroid peroxidase antibodies (anti-ThyPeroxAb), and lupus anticoagulant (LAC).

Hematologists at Massachusetts General Hospital (Boston, MA, USA) and their colleague performed retrospective review of patients with ITP presenting to their center from 1 January 1992 to 1 December 2015. ANA assays were performed by indirect immunofluorescence assay, using Hep-2 cells (Zeus Scientific, Inc, Branchburg, NJ, USA). ThyPeroxAb assays were performed at Quest Diagnostics (Secaucus, NJ, USA) using an immunoassay method. RF markers were measured with an immunoturbidimetric assay on a cobas c 502 platform (Roche, Basel, Switzerland). Positive results for ACL were defined as >15 for IgG phospholipid units or IgM phospholipid (MPL) units. Glycoprotein-specific direct platelet autoantibody testing was performed with the PakAuto assay (Immucor, Brookfield, WI, USA).

The scientists reported that there was a high rate of autoimmune marker positivity in this population, with antinuclear antibody (65%), antithyroid peroxidase antibody (31%), and direct antiglobulin (29%) the most commonly found. Antithyroid peroxidase antibody positivity was associated with a lower probability of remission (odds ratio [OR], 0.26). Lupus anticoagulant positivity was associated with a higher rate of thrombosis (OR, 8.92), and antinuclear antibody was strongly associated with thrombosis. There was no relation between platelet autoantibody positivity and the presence of autoimmune markers.

The authors concluded that their results suggest that many patients with ITP have a state of immune dysregulation that extends beyond platelet autoantibodies and that certain autoimmune markers may be prognostically useful in this disorder. The study was published on November 15, 2019 in the journal Blood Advances.

Related Links:
Massachusetts General Hospital
Zeus Scientific
Quest Diagnostics
Roche
Immucor


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.